Greg Fahy, PhD
Co-Founder and CSO of Intervene Immune, USA
Dr. Fahy is Vice President and Chief Scientific Officer at Twenty-First Century Medicine, Inc and Co-Founder and Chief Scientific Officer of Intervene Immune, a company developing clinical methods to reverse immune system aging.
Dr. Fahy is the world's foremost expert in organ cryopreservation by vitrification. Dr. Fahy introduced the modern successful approach to vitrification for cryopreservation in cryobiology and he is widely credited, along with William F. Rall, for introducing vitrification into the field of reproductive biology. In the summer of 2005, where he was a keynote speaker at the annual Society for Cryobiology meeting, Dr. Fahy announced that Twenty-First Century Medicine had successfully cryopreserved a rabbit kidney at -130 °C by vitrification and transplanted it into a rabbit after rewarming, with subsequent long-term life support by the vitrified-rewarmed kidney as the sole kidney. This research breakthrough was later published in the peer-reviewed journal Organogenesis.
Dr. Fahy is also a well-known biogerontologist and is the originator and Editor-in-Chief of The Future of Aging: Pathways to Human Life Extension, a multi-authored book on the future of biogerontology. He currently serves on the editorial boards of Rejuvenation Research and the Open Geriatric Medicine Journal and served for 16 years as a Director of the American Aging Association and for 6 years as the editor of AGE News, the organization's newsletter.
Dr. Fahy has over thirty years of experience in the field of cryopreservation. As a scientist with the American Red Cross, he was the originator of the first practical method of cryopreservation by vitrification and the inventor of computer-based systems to apply this technology to whole organs. Before joining Twenty-First Century Medicine, he was the chief scientist for Organ, Inc and of LRT, Inc. He was also Head of the Tissue Cryopreservation Section of the Transfusion and Cryopreservation Research Program of the U.S. Naval Medical Research Institute in Bethesda, Maryland where he spearheaded the original concept of ice blocking agents. In 2014, he was named a Fellow of the Society for Cryobiology in recognition of the impact of his work in low temperature biology.
In 2015–2017, Fahy led the TRIIM (Thymus Regeneration, Immunorestoration, and Insulin Mitigation) human clinical trial, designed to reverse aspects of human aging. The purpose of the TRIIM trial was to investigate the possibility of using recombinant human growth hormone (rhGH) to prevent or reverse signs of immunosenescence in ten 51‐to 65‐year‐old putatively healthy men. The study observed protective immunological changes, improved risk indices for many age‐related diseases, and a mean epigenetic age approximately 1.5 years less than baseline after 1 year of treatment (−2.5‐year change compared to no treatment at the end of the study).
A native of California, Fahy holds a Bachelor of Science degree in Biology from the University of California, Irvine and a Ph.D. in pharmacology from the Medical College of Georgia in Augusta. He currently serves on the board of directors of two organizations and as a referee for numerous scientific journals and funding agencies, and holds 35 patents on cryopreservation methods, aging interventions, transplantation, and other topics.